At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 5, 2026 at 06:00 ET
HUTCHMED reported mixed financial results for 2025, with a significant $457 million net income driven by a $416 million gain from the divestment of SHPL, but core oncology revenue declined 21% to $214.4 million. Despite a 5% increase in in-market sales and strong clinical progress across its pipeline, including positive Phase III data and regulatory approvals, underlying commercial performance in China weakened. The company maintains a robust $1.4 billion cash balance and provided 2026 oncology revenue guidance of $330–450 million, while advancing its novel ATTC platform into clinical trials.
- Net income attributable to HUTCHMED was $456.9 million in 2025 (vs. $37.7 million in 2024), primarily due to a $415.8 million after-tax gain from the divestment of a 45% stake in SHPL.
- Total consolidated revenue declined 13% to $548.5 million, with oncology/immunology revenue down 21% to $285.5 million.
- In-market sales grew 5% to $524.7 million, led by 26% growth in FRUZAQLA® (ex-China) to $366.2 million, but offset by declines in ELUNATE®, SULANDA®, and ORPATHYS® in China.
- Oncology product revenue in China declined, though second-half 2025 sales grew 23% sequentially after commercial team restructuring.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access